These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25668913)

  • 1. [Major milestones for European pharmaceutical policy].
    Sauer F
    Rev Hist Pharm (Paris); 2014 Jan; 62(381):61-74. PubMed ID: 25668913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
    Enzmann H; Broich K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International harmonisation - the need for transparency.
    Hodgkin C
    Int J Risk Saf Med; 1996; 9(3):195-9. PubMed ID: 23510917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of European harmonisation on Norwegian drug policy.
    Norris P
    Health Policy; 1998 Jan; 43(1):65-81. PubMed ID: 10178802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International harmonisation of regulatory requirements.
    Holmes M; Hill RE
    Rev Sci Tech; 2007 Aug; 26(2):415-20. PubMed ID: 17892161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [European drug policy].
    Sauer F
    Bull Mem Acad R Med Belg; 1993; 148(5-6):207-12; discussion 212-6. PubMed ID: 8142930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for use in the International Conference on Harmonisation Regions; Annex 4C on Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15992-3. PubMed ID: 19507323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European regulations relevant to the marketing and use of fish vaccines.
    Lee A
    Dev Biol Stand; 1997; 90():341-6. PubMed ID: 9270862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Conference on Harmonisation; revised guidance on Q3B(R) Impurities in New Drug Products; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Nov; 68(220):64628-9. PubMed ID: 14619944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Europe and medicines: role of the EMEA].
    Sauer F
    Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selected aspects of europeization of pharmaceutical law.
    Zimmermann A; Wengler L; Pawłowski L
    Acta Pol Pharm; 2010; 67(2):205-10. PubMed ID: 20369799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.
    Vella Bonanno P; Cassar V; Godman B
    Front Pharmacol; 2021; 12():666405. PubMed ID: 34867312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.